Vor Biopharma (VOR) Cash from Financing Activities (2020 - 2026)
Vor Biopharma (VOR) reported Cash from Financing Activities of $74.9 million for Q1 2026, up 12454.79% year-over-year from N/an in Q1 2025, and down 75.68% on a QoQ basis from $307.8 million in Q4 2025.
Vor Biopharma (VOR) has 7 years of Cash from Financing Activities data on file, last reported at $74.9 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 12454.79% year-over-year to $74.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $579.3 million (up 999.42% YoY) and the FY2025 annual result came in at $503.8 million, up 843.6% from the prior year.
- Cash from Financing Activities eased to $74.9 million in Q1 2026 per VOR's latest filing, from $307.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $307.8 million in Q4 2025 and bottomed at -$606000.0 in Q1 2025.
- The 5-year median for Cash from Financing Activities is $604000.0 (2022), against an average of $44.2 million.
- Peak annual rise in Cash from Financing Activities reached 564825.81% in 2025, while the deepest fall reached 731.25% in 2025.
- Tracing VOR's Cash from Financing Activities over 5 years: stood at $112.3 million in 2022, then plunged by 99.98% to $25000.0 in 2023, then surged by 213044.0% to $53.3 million in 2024, then jumped by 477.64% to $307.8 million in 2025, then tumbled by 75.68% to $74.9 million in 2026.
- Per Business Quant, the three latest VOR Cash from Financing Activities figures stand at $74.9 million (Q1 2026), $307.8 million (Q4 2025), and $21.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - | 74.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.87 Mn |
| Mar 31, 2026 | 74.87 Mn |
| Dec 31, 2025 | 307.80 Mn |
| Dec 31, 2025 | 307.80 Mn |
| Sep 30, 2025 | 21.55 Mn |
| Sep 30, 2025 | 21.55 Mn |
| Jun 30, 2025 | 175.07 Mn |
| Jun 30, 2025 | 175.07 Mn |
| Mar 31, 2025 | -606,000.00 |
| Mar 31, 2025 | -606,000.00 |
| Dec 31, 2024 | 53.29 Mn |
| Dec 31, 2024 | 53.29 Mn |
| Sep 30, 2024 | 41,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Jun 30, 2024 | -31,000.00 |
| Jun 30, 2024 | -31,000.00 |
| Mar 31, 2024 | 96,000.00 |
| Mar 31, 2024 | 96,000.00 |
| Dec 31, 2023 | 25,000.00 |
| Dec 31, 2023 | 25,000.00 |
| Sep 30, 2023 | 176,000.00 |
| Sep 30, 2023 | 176,000.00 |
| Jun 30, 2023 | 218,000.00 |
| Jun 30, 2023 | 218,000.00 |
| Mar 31, 2023 | 2.52 Mn |
| Mar 31, 2023 | 2.52 Mn |
| Dec 31, 2022 | 112.26 Mn |
| Dec 31, 2022 | 112.26 Mn |
| Sep 30, 2022 | 4.08 Mn |
| Sep 30, 2022 | 4.08 Mn |
| Jun 30, 2022 | 604,000.00 |
| Jun 30, 2022 | 604,000.00 |
| Mar 31, 2022 | 200,000.00 |
| Mar 31, 2022 | 200,000.00 |
| Dec 31, 2021 | 307,000.00 |
| Dec 31, 2021 | 307,000.00 |
| Sep 30, 2021 | 201,000.00 |
| Sep 30, 2021 | 201,000.00 |
| Jun 30, 2021 | -445,000.00 |
| Jun 30, 2021 | -445,000.00 |
| Mar 31, 2021 | 232.85 Mn |
| Mar 31, 2021 | 232.85 Mn |
| Dec 31, 2020 | 46,000.00 |
| Dec 31, 2020 | 46,000.00 |
| Sep 30, 2020 | 526,000.00 |
| Sep 30, 2020 | 526,000.00 |
| Jun 30, 2020 | 64.19 Mn |
| Jun 30, 2020 | 64.19 Mn |
| Mar 31, 2020 | 17.76 Mn |
| Mar 31, 2020 | 17.76 Mn |